AR093532A1 - Compuestos y composiciones para el tratamiento de enfermedades parasitarias - Google Patents
Compuestos y composiciones para el tratamiento de enfermedades parasitariasInfo
- Publication number
- AR093532A1 AR093532A1 ARP130104250A ARP130104250A AR093532A1 AR 093532 A1 AR093532 A1 AR 093532A1 AR P130104250 A ARP130104250 A AR P130104250A AR P130104250 A ARP130104250 A AR P130104250A AR 093532 A1 AR093532 A1 AR 093532A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- halo
- heteroaryl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Se proporciona además composiciones farmacéuticas que comprenden tales compuestos y el uso de tales compuestos para tratar, prevenir, inhibir, mejorar, o erradicar la patología y/o sintomatología de una enfermedad causada por un parásito Plasmodium, como por ejemplo la malaria. Reivindicación 1: Un compuesto de la fórmula (1), o una sal farmacéuticamente aceptable, tautómero o estereoisómero del mismo, en donde n es 0, 1, 2 ó 3; p es 0, 1, 2 ó 3; L se selecciona del grupo que consta de *-(CHR³)₁₋₃-, *-CHR³N(R²)-, *-CHR³O-, *-CHR³S-, *-CHR³S(O)-, *-CHR³N(R²)CHR³-, *-C(O)-, *-C(O)N(R²)-, *-C(O)N(R²)CHR³-, *-N(R²)-, *-N(R²)CHR³-, *-N(R²)C(O)-, *-N(R²)C(O)N(R²)-, *-N(R²)S(O)₂-, en donde * representa el punto de unión de L al anillo fusionado a pirazolo[1,5-a]piridina ilustrado en la fórmula (1); cada R² se selecciona independientemente del grupo que consta de hidrógeno, alquilo C₁₋₆, halo-alquilo C₁₋₆, R-alquileno C₀₋₄, y R-alquileno C₀₋₄-C(O)-, en donde R se selecciona del grupo que consta de hidroxilo, alcoxilo C₁₋₄, amino, alquil C₁₋₄amino, cicloalquilo C₃₋₆, heterocicloalquilo C₄₋₆, y heteroarilo C₅₋₆, en donde el cicloalquilo C₃₋₆, heterocicloalquilo C₄₋₆, y heteroarilo C₅₋₆ de R son cada uno sustituidos o no sustituidos por 1 - 2 sustituyentes independientemente seleccionados del grupo que consta de halo, amino, hidroxilo, alquilo C₁₋₄, alcoxilo C₁₋₄, oxo, y heteroarilo C₅₋₆; y cada R³ se selecciona independientemente del grupo que consta de hidrógeno y alquilo C₁₋₄; el anillo A se selecciona del grupo que consta de arilo C₆₋₁₀ y heteroarilo C₅₋₁₀; el anillo C se selecciona del grupo que consta de arilo C₆₋₁₀, heteroarilo C₅₋₁₀, cicloalquilo C₅₋₇, heterocicloalquilo C₅₋₇, y biciclilo fusionado que comprende un heterocicloalquilo C₅₋₆ fusionado a fenilo; cada R¹ se selecciona independientemente del grupo que consta de halo, ciano, amino, alquilo C₁₋₄, alcoxilo C₁₋₄, halo-alquilo C₁₋₄, -C(O)NR⁷R⁸, -NHC(O)R¹¹, fenilo, y heteroarilo C₅₋₆; en donde el fenilo y heteroarilo C₅₋₆ de R¹ son cada uno sustituidos o no sustituidos por 1 - 2 sustituyentes independientemente seleccionados del grupo que consta de alquilo C₁₋₄, amino, halo, y alquil C₁₋₄amino; R⁷ y R⁸ son cada uno independientemente seleccionados de hidrógeno, alquilo C₁₋₄ y halo-alquilo C₁₋₄; R¹¹ es alquilo C₁₋₆, sustituido o no sustituido por 1 - 2 sustituyentes independientemente seleccionados del grupo que consta de amino, cicloalquilo C₃₋₆ y heterocicloalquilo C₄₋₆; R¹⁷ se selecciona del grupo que consta de ciano, halo, alquilo C₁₋₄, halo-alquilo C₁₋₄, oxo, cicloalquilo C₃₋₆, y -SO₂-alquilo C₁₋₄.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728018P | 2012-11-19 | 2012-11-19 | |
US201361847860P | 2013-07-18 | 2013-07-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR093532A1 true AR093532A1 (es) | 2015-06-10 |
Family
ID=49667630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130104250A AR093532A1 (es) | 2012-11-19 | 2013-11-19 | Compuestos y composiciones para el tratamiento de enfermedades parasitarias |
Country Status (19)
Country | Link |
---|---|
US (3) | US9556169B2 (es) |
EP (1) | EP2925757B1 (es) |
JP (1) | JP6298472B2 (es) |
CN (1) | CN105164124B (es) |
AR (1) | AR093532A1 (es) |
CY (1) | CY1119727T1 (es) |
DK (1) | DK2925757T3 (es) |
ES (1) | ES2655030T3 (es) |
HR (1) | HRP20171998T1 (es) |
HU (1) | HUE037600T2 (es) |
LT (1) | LT2925757T (es) |
ME (1) | ME03042B (es) |
PL (1) | PL2925757T3 (es) |
PT (1) | PT2925757T (es) |
RS (1) | RS56720B1 (es) |
SI (1) | SI2925757T1 (es) |
TW (1) | TWI600654B (es) |
UY (1) | UY35146A (es) |
WO (1) | WO2014078802A1 (es) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41338B1 (fr) * | 2015-01-16 | 2019-07-31 | Hoffmann La Roche | Composés de pyrazine pour le traitement de maladies infectieuses |
MX2018008941A (es) | 2016-01-21 | 2018-09-03 | Novartis Ag | Compuestos y composiciones para el tratamiento de la criptoporidiosis. |
TWI696615B (zh) * | 2016-05-05 | 2020-06-21 | 瑞士商伊蘭科動物健康公司 | 雜芳基-1,2,4-三唑及雜芳基-三唑化合物 |
JP7051804B2 (ja) * | 2016-07-14 | 2022-04-11 | エフ.ホフマン-ラ ロシュ アーゲー | 感染症の治療のための6,7-ジヒドロ-4H-ピラゾロ[1,5-a]ピラジン化合物と6,7-ジヒドロ-4H-トリアゾロ[1,5-a]ピラジン化合物 |
BR112019007594A2 (pt) * | 2016-10-13 | 2019-07-02 | Loyola University Of Chicago | método para bloquear a transmissão do parasita da malária |
EP3609504A4 (en) | 2017-03-01 | 2021-03-03 | Anacor Pharmaceuticals, Inc. | NEW OXABOROLE ANALOGUES AND USES OF THE LATEST |
JP7306997B2 (ja) | 2017-03-20 | 2023-07-11 | ザ・ブロード・インスティテュート・インコーポレイテッド | 寄生虫性疾患の処置のための化合物および方法 |
WO2018176134A1 (en) | 2017-03-27 | 2018-10-04 | HYDRO-QUéBEC | Salts for use in electrolyte compositions or as electrode additives |
CN107037148B (zh) * | 2017-04-07 | 2019-11-19 | 上海药明康德新药开发有限公司 | 卤泛曲林的高效液相检测方法 |
JOP20190278A1 (ar) | 2017-05-31 | 2019-11-28 | Novartis Ag | مركبات 5، 6-ثنائية الحلقة مندمجة وتركيبات لعلاج الأمراض الطفيلية |
US20220048903A1 (en) * | 2018-07-09 | 2022-02-17 | Boehringer Ingelheim Animal Health USA Inc. | Anthelminthic Heterocyclic Compounds |
GB201811695D0 (en) * | 2018-07-17 | 2018-08-29 | Salvensis | Compounds for use in the treatment of fascioliasis |
WO2020191091A1 (en) | 2019-03-19 | 2020-09-24 | Boehringer Ingelheim Animal Health USA Inc. | Anthelmintic aza-benzothiophene and aza-benzofuran compounds |
CN114206860A (zh) * | 2019-06-07 | 2022-03-18 | 礼蓝动物保健有限公司 | 用于治疗体内寄生虫的双环衍生物 |
BR112022024156A2 (pt) | 2020-05-29 | 2023-02-14 | Boehringer Ingelheim Animal Health Usa Inc | Compostos heterocílicos antelmínticos |
WO2023275590A1 (en) | 2021-06-29 | 2023-01-05 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Detection of phosphoinositides in blood cells as a biomarker for alpha synuclein associated pathologies and a method of treatment of parkinson's disease and the related neurodegenerations |
WO2023057394A1 (en) | 2021-10-04 | 2023-04-13 | Forx Therapeutics Ag | N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer |
AU2022377394A1 (en) | 2021-11-01 | 2024-06-13 | Boehringer Ingelheim Vetmedica Gmbh | Anthelmintic pyrrolopyridazine compounds |
CA3181279A1 (en) * | 2022-03-24 | 2023-09-24 | Bloom Energy Corporation | Fuel cell stack assembly including heat sink inserts |
WO2024006974A2 (en) * | 2022-07-01 | 2024-01-04 | The Scripps Research Institute | Antimalarial compounds |
US20240124450A1 (en) | 2022-09-21 | 2024-04-18 | Pfizer Inc. | Novel SIK Inhibitors |
Family Cites Families (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH11505524A (ja) | 1995-05-01 | 1999-05-21 | 藤沢薬品工業株式会社 | イミダゾ1,2−aピリジンおよびイミダゾ1,2−aピリデジン誘導体、および骨吸収阻害剤としてのその用途 |
AU747708B2 (en) | 1996-07-24 | 2002-05-23 | Du Pont Pharmaceuticals Company | Azolo triazines and pyrimidines |
KR20010014183A (ko) | 1997-06-27 | 2001-02-26 | Fujisawa Pharmaceutical Co | 술폰아미드 화합물 및 그의 의약 용도 |
JP2001139575A (ja) | 1999-11-15 | 2001-05-22 | Fujisawa Pharmaceut Co Ltd | 新規ピラゾロピリジン誘導体 |
GB0002336D0 (en) | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
GB0002312D0 (en) | 2000-02-01 | 2000-03-22 | Glaxo Group Ltd | Medicaments |
ES2317889T3 (es) * | 2000-03-01 | 2009-05-01 | Janssen Pharmaceutica Nv | Derivados de tiazolilo 2,4-disustituido. |
JP2003531906A (ja) | 2000-04-28 | 2003-10-28 | グラクソ グループ リミテッド | ピラゾロピリジン誘導体の製造方法 |
GB0018473D0 (en) | 2000-07-27 | 2000-09-13 | Merck Sharp & Dohme | Therapeutic agents |
PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
AUPQ969800A0 (en) | 2000-08-28 | 2000-09-21 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
US7074801B1 (en) | 2001-04-26 | 2006-07-11 | Eisai Co., Ltd. | Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof |
AUPR916301A0 (en) | 2001-11-29 | 2001-12-20 | Fujisawa Pharmaceutical Co., Ltd. | Pyrazolopyridine compound and pharmaceutical use thereof |
MXPA04010441A (es) | 2002-04-23 | 2005-02-14 | Shionogi & Co | Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo. |
US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
US8673924B2 (en) | 2002-09-04 | 2014-03-18 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
DE60315677T2 (de) | 2002-09-17 | 2008-06-05 | Eli Lilly And Co., Indianapolis | Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
WO2006019768A1 (en) * | 2004-07-16 | 2006-02-23 | Schering Corporation | Hydantoin derivatives for the treatment of inflammatory disorders |
US7488745B2 (en) | 2004-07-16 | 2009-02-10 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
US7504424B2 (en) | 2004-07-16 | 2009-03-17 | Schering Corporation | Compounds for the treatment of inflammatory disorders |
TW200615268A (en) | 2004-08-02 | 2006-05-16 | Osi Pharm Inc | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
AU2005295734A1 (en) | 2004-10-15 | 2006-04-27 | Biogen Idec Ma Inc. | Methods of treating vascular injuries |
JP4935357B2 (ja) | 2004-11-08 | 2012-05-23 | Msd株式会社 | 新規縮環イミダゾール誘導体 |
DE602005014382D1 (de) * | 2004-12-21 | 2009-06-18 | Smithkline Beecham Corp | 2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren |
EP1832588A4 (en) | 2004-12-28 | 2009-09-02 | Takeda Pharmaceutical | IMIDAZOLE CONDENSE DERIVATIVE AND APPLICATIONS THEREOF |
US7713975B1 (en) | 2005-01-12 | 2010-05-11 | Alcon, Inc. | 3,6-substituted imidazol[1,2-b]pyridazine analogs for treating allergic and inflammatory diseases |
WO2007013673A1 (en) | 2005-07-29 | 2007-02-01 | Astellas Pharma Inc. | Fused heterocycles as lck inhibitors |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
DE102005042742A1 (de) | 2005-09-02 | 2007-03-08 | Schering Ag | Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel |
TW200800213A (en) | 2005-09-02 | 2008-01-01 | Abbott Lab | Novel imidazo based heterocycles |
EP2407459A1 (en) | 2005-09-27 | 2012-01-18 | Shionogi & Co., Ltd. | Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity |
WO2007067537A1 (en) | 2005-12-07 | 2007-06-14 | Osi Pharmaceuticals, Inc. | Pyrrolopyridine kinase inhibiting compounds |
RU2008127263A (ru) | 2005-12-08 | 2010-01-20 | Новартис АГ (CH) | ПИРАЗОЛ [1,5-a] ПИРИДИН-3-КАРБОНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ EphB-И VEGFR2-КИНАЗЫ |
WO2007086080A2 (en) | 2006-01-30 | 2007-08-02 | Glenmark Pharmaceuticals Limited | NOVEL IMIDAZO[1,2-a]PYRIDINE CANNABINOID RECEPTOR LIGANDS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO2007096764A2 (en) | 2006-02-27 | 2007-08-30 | Glenmark Pharmaceuticals S.A. | Bicyclic heteroaryl derivatives as cannabinoid receptor modulators |
CA2643802A1 (en) | 2006-02-27 | 2007-09-07 | Alexander Michalow | Methods for regulating neurotransmitter systems by inducing counteradaptations |
JP5352452B2 (ja) | 2006-06-06 | 2013-11-27 | メディシノバ, インコーポレイテッド | 置換ピラゾロ[1,5−a]ピリジン化合物およびその使用方法 |
EP1873157A1 (en) | 2006-06-21 | 2008-01-02 | Bayer Schering Pharma Aktiengesellschaft | Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same |
DE102006029447A1 (de) | 2006-06-21 | 2007-12-27 | Bayer Schering Pharma Ag | Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel |
EP1900739A1 (en) | 2006-08-30 | 2008-03-19 | Cellzome Ag | Diazolodiazine derivatives as kinase inhibitors |
WO2008030579A2 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder |
JP2010503383A (ja) | 2006-09-12 | 2010-02-04 | ザ ジェネラル ホスピタル コーポレイション | 細胞シグナリングをモジュレートする化合物を同定するための方法およびこのような化合物を使用する方法 |
US20090286779A1 (en) | 2006-09-29 | 2009-11-19 | Novartis Ag | Pyrazolopyrimidines as lipid kinase inhibitors |
CN101522682A (zh) | 2006-10-30 | 2009-09-02 | 诺瓦提斯公司 | 作为抗炎剂的杂环化合物 |
AU2007316417B2 (en) | 2006-11-06 | 2013-08-22 | Tolero Pharmaceuticals, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
WO2008072682A1 (ja) | 2006-12-15 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾ[1,2-b]ピリダジン誘導体 |
AR064420A1 (es) | 2006-12-21 | 2009-04-01 | Alcon Mfg Ltd | Composiciones farmaceuticas oftalmicas que comprenden una cantidad efectiva de analogos de 6-aminoimidazo[1,2b]piridazinas, utiles para el tratamiento del glaucoma y/o controlar la presion intraocular normal o elevada(iop). |
CN101679408B (zh) | 2006-12-22 | 2016-04-27 | Astex治疗学有限公司 | 作为fgfr抑制剂的双环杂环化合物 |
JP2010516774A (ja) | 2007-01-26 | 2010-05-20 | アイアールエム・リミテッド・ライアビリティ・カンパニー | マラリア原虫関連疾患を処置するためのキナーゼ阻害剤としてのプリン化合物および組成物 |
WO2008156783A2 (en) | 2007-06-18 | 2008-12-24 | University Of Louisville Research Foundation, Inc. | Family of pfkfb3 inhibitors with anti-neoplastic activities |
AU2008273050A1 (en) | 2007-07-11 | 2009-01-15 | Auckland Uniservices Limited | Pyrazolo[1,5-a]pyridines and their use in cancer therapy |
UA105758C2 (uk) | 2007-07-19 | 2014-06-25 | Х. Луннбек А/С | 5-членні гетероциклічні аміди та споріднені сполуки |
WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
PE20091468A1 (es) | 2008-02-28 | 2009-10-22 | Novartis Ag | DERIVADOS DE 3-METIL-IMIDAZO-[1,2-b]-PIRIDAZINA |
JP5638961B2 (ja) * | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Bmpシグナル伝達経路のインヒビター |
US8507488B2 (en) | 2008-05-13 | 2013-08-13 | Irm Llc | Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors |
JP2009298710A (ja) | 2008-06-11 | 2009-12-24 | Daiichi Sankyo Co Ltd | イミダゾ[1,2−b]ピリダジン誘導体含有医薬組成物 |
EP2310492B1 (en) | 2008-06-30 | 2015-07-22 | Janssen Biotech, Inc. | Differentiation of pluripotent stem cells |
EP2320737B1 (en) | 2008-08-05 | 2013-07-17 | Merck Sharp & Dohme Corp. | Pyrazolo-[1,5-a]-pyridines as mark inhibitors |
JP2011530511A (ja) | 2008-08-05 | 2011-12-22 | メルク・シャープ・エンド・ドーム・コーポレイション | 治療用化合物 |
US8293909B2 (en) | 2008-09-11 | 2012-10-23 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
US8198449B2 (en) | 2008-09-11 | 2012-06-12 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
JP2012503623A (ja) | 2008-09-24 | 2012-02-09 | ビーエーエスエフ ソシエタス・ヨーロピア | 無脊椎動物系害虫防除用ピラゾール化合物 |
WO2010059836A1 (en) | 2008-11-20 | 2010-05-27 | Decode Genetics Ehf | Substituted aza-bridged bicyclics for cardiovascular and cns disease |
JP2012510983A (ja) | 2008-12-04 | 2012-05-17 | プロキシマジェン エルティーディー | イミダゾピリジン化合物 |
WO2010074586A1 (en) | 2008-12-23 | 2010-07-01 | Pathway Therapeutics Limited | Pyrazolo[1,5-a]pyridine and imidazo[1,2-a]pyridine derivatives and their use in cancer therapy |
CN102395585A (zh) | 2009-01-30 | 2012-03-28 | 米伦纽姆医药公司 | 杂芳基化合物和其作为pi3k抑制剂的用途 |
US8969342B2 (en) | 2009-03-20 | 2015-03-03 | Brandeis University | Compounds and methods for treating mammalian gastrointestinal microbial infections |
AU2010226490A1 (en) | 2009-03-20 | 2011-10-06 | Amgen Inc. | Inhibitors of PI3 kinase |
WO2010117787A2 (en) | 2009-03-30 | 2010-10-14 | The Brigham And Women's Hospital, Inc. | Inhibiting eph b-3 kinase |
EP2417138B1 (en) | 2009-04-09 | 2019-11-27 | Merck Sharp & Dohme Corp. | Pyrazolo[1, 5-a]pyrimidine derivatives as mtor inhibitors |
AR077463A1 (es) * | 2009-07-09 | 2011-08-31 | Irm Llc | Derivados de imidazo[1, 2 - a]pirazina y su uso en medicamentos para el tratamiento de enfermedades parasitarias |
RU2421455C2 (ru) | 2009-07-14 | 2011-06-20 | Государственное образовательное учреждение высшего профессионального образования "Пермский государственный университет" | СПОСОБ ПОЛУЧЕНИЯ МЕТИЛ 7-АРИЛКАРБАМОИЛ-6-БЕНЗОИЛ-2-МЕТИЛ-3-ФЕНИЛПИРАЗОЛО[1,5-a]ПИРИМИДИН-5-КАРБОКСИЛАТОВ |
TW201107329A (en) | 2009-07-30 | 2011-03-01 | Oncotherapy Science Inc | Fused imidazole derivative having ttk inhibitory action |
TW201113286A (en) | 2009-09-03 | 2011-04-16 | Array Biopharma Inc | Substituted pyrazolo[1,5-a]pyrimidine compounds as mTOR inhibitors |
JP2013506624A (ja) | 2009-09-23 | 2013-02-28 | アミラ ファーマシューティカルズ,インク. | 5−リポキシゲナーゼのインドリジンインヒビター |
GB201002911D0 (en) | 2010-02-19 | 2010-04-07 | Medical Res Council | Compound |
JP2016500073A (ja) | 2012-11-19 | 2016-01-07 | ノバルティス アーゲー | 寄生虫病の処置のための化合物および組成物 |
-
2013
- 2013-11-18 ME MEP-2017-266A patent/ME03042B/me unknown
- 2013-11-18 CN CN201380070822.0A patent/CN105164124B/zh not_active Expired - Fee Related
- 2013-11-18 LT LTEP13795977.1T patent/LT2925757T/lt unknown
- 2013-11-18 RS RS20171296A patent/RS56720B1/sr unknown
- 2013-11-18 ES ES13795977.1T patent/ES2655030T3/es active Active
- 2013-11-18 EP EP13795977.1A patent/EP2925757B1/en active Active
- 2013-11-18 PT PT137959771T patent/PT2925757T/pt unknown
- 2013-11-18 PL PL13795977T patent/PL2925757T3/pl unknown
- 2013-11-18 WO PCT/US2013/070601 patent/WO2014078802A1/en active Application Filing
- 2013-11-18 JP JP2015542882A patent/JP6298472B2/ja not_active Expired - Fee Related
- 2013-11-18 TW TW102141950A patent/TWI600654B/zh not_active IP Right Cessation
- 2013-11-18 HU HUE13795977A patent/HUE037600T2/hu unknown
- 2013-11-18 US US14/443,609 patent/US9556169B2/en active Active
- 2013-11-18 SI SI201330889T patent/SI2925757T1/en unknown
- 2013-11-18 DK DK13795977.1T patent/DK2925757T3/en active
- 2013-11-19 AR ARP130104250A patent/AR093532A1/es unknown
- 2013-11-19 UY UY0001035146A patent/UY35146A/es unknown
-
2016
- 2016-07-26 US US15/220,149 patent/US9926314B2/en not_active Expired - Fee Related
-
2017
- 2017-12-27 HR HRP20171998TT patent/HRP20171998T1/hr unknown
-
2018
- 2018-01-03 CY CY20181100008T patent/CY1119727T1/el unknown
- 2018-02-06 US US15/889,578 patent/US20180230145A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
HUE037600T2 (hu) | 2018-09-28 |
JP6298472B2 (ja) | 2018-03-20 |
RS56720B1 (sr) | 2018-03-30 |
EP2925757A1 (en) | 2015-10-07 |
WO2014078802A1 (en) | 2014-05-22 |
HRP20171998T1 (hr) | 2018-02-09 |
US9926314B2 (en) | 2018-03-27 |
TWI600654B (zh) | 2017-10-01 |
PL2925757T3 (pl) | 2018-06-29 |
LT2925757T (lt) | 2017-12-27 |
US20180230145A1 (en) | 2018-08-16 |
EP2925757B1 (en) | 2017-10-04 |
CY1119727T1 (el) | 2018-06-27 |
US20150344471A1 (en) | 2015-12-03 |
PT2925757T (pt) | 2018-01-09 |
ME03042B (me) | 2018-10-20 |
US9556169B2 (en) | 2017-01-31 |
US20160333012A1 (en) | 2016-11-17 |
JP2016505529A (ja) | 2016-02-25 |
DK2925757T3 (en) | 2018-01-15 |
CN105164124A (zh) | 2015-12-16 |
UY35146A (es) | 2014-06-30 |
SI2925757T1 (en) | 2018-01-31 |
TW201429967A (zh) | 2014-08-01 |
ES2655030T3 (es) | 2018-02-16 |
CN105164124B (zh) | 2017-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR093532A1 (es) | Compuestos y composiciones para el tratamiento de enfermedades parasitarias | |
CO2019008531A2 (es) | Análogos de atazanavir (atv) para tratar infecciones por vih. | |
AR091093A1 (es) | Tienopirimidinas | |
CU20150014A7 (es) | Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn | |
AR090847A1 (es) | Compuestos moduladores del receptor huerfano retinoideo (ror) | |
AR091628A1 (es) | 7h-pirrolo[2,3-d]pirimidinas 4-(amino-substituidas) como inhibidores de lrrk2 | |
AR106865A1 (es) | Piridinas sustituidas y métodos de uso | |
AR103251A1 (es) | Compuestos policíclicos de carbamoilpiridona y su uso farmacéutico | |
CO2018011408A2 (es) | Compuestos de pirimidina como inhibidores de la quinasa jak | |
AR090292A1 (es) | Compuestos basados en pirazolo[1,5-a]pirimidina, composiciones que los comprenden y metodos que los utilizan | |
MY180666A (en) | Substituted pyrazolo [3,4-b] pyridines as medicaments | |
PE20221914A1 (es) | Compuestos de benzaldehido sustituidos y metodos para su uso en incrementar la oxigenacion del tejido | |
AR083879A1 (es) | Analogos de aminoglicosidos antibacterianos, metodos de preparacion y uso como agentes terapeuticos | |
AR086546A1 (es) | Derivados de 7h-purin-8(9h)-ona como inhibidores de jak | |
RU2013142448A (ru) | Новые сульфонаминохинолиновые антагонисты гепсидина | |
EA201500298A1 (ru) | Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы | |
AR091156A1 (es) | Nucleosidos de espirooxetano de uracilo | |
AR108046A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue | |
AR092045A1 (es) | Combinaciones farmaceuticas | |
AR087913A1 (es) | Inhibidores sustituidos de n-[1-ciano-2-(fenil)etil]-2-azabiciclo[2,2,1]heptan-3-carboxamida de catepsina c | |
CL2012000042A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazin-7-il; composición farmacéutica que comprende a uno de los compuestos; y uso de uno de los compuestos en la preparación de un medicamento útil para tratar una enfermedad relacionada con el género plasmodium en un sujeto. | |
PE20190504A1 (es) | Moduladores del receptor nmda espiro-lactam y uso de los mismos | |
PE20220806A1 (es) | Pirazolo piridinas heteroaromaticas sustituidas y su uso como moduladores del receptor glun2b | |
EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 | |
AR107054A1 (es) | DERIVADOS DE ISOINDOL Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR RORg Y RORgt |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |